THE Competition and Consumer Commission of Singapore is inviting public feedback on the two-year commitments proposed by Pathology Asia Holdings to address competition concerns in the planned merger of two private clinical laboratories.
It said that it is entering into the four commitments even though it “disagrees with the concerns identified by the CCCS”, and that it believes that the merger does not result in substantially reducing competition in any market in Singapore. PAH is also committing to allow early termination of contracts without cause. Likewise, this enables customers to more easily switch to other labs.
Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше: